Andrew H. Walton

TL;DR: Patients who die in the ICU following sepsis compared with patients who die of nonsepsis etiologies have biochemical, flow cytometric, and immunohistochemical findings consistent with immunosuppression, and targeted immune-enhancing therapy may be a valid approach in selected patients with sepsi.

TL;DR: In this article, rapid postmortem spleen and lung tissue harvest was performed at the bedsides of 40 patients who died in intensive care units (ICUs) of academic medical centers with active severe sepsis to characterize their immune status at the time of death (2009-2011).

TL;DR: It is hypothesized that reactivation of latent viruses occurred with prolonged sepsis thereby providing evidence of clinically-relevant immunosuppression and potentially providing a means to serially-monitor patients' immune status and if viral loads are markedly elevated, they may contribute to morbidity and mortality.

TL;DR: The hypothesis that COVID-19 suppresses host functional adaptive and innate immunity is supported and IL-7 administered ex vivo restored T cell IFN-ɣ production in CO VID-19 patients, and ELISpot may functionally characterize host immunity in COvid-19 and inform prospective therapies.

TL;DR: This is the first trial of an immunoadjuvant therapy targeting defects in adaptive immunity in patients with sepsis and CYT107 reversed the marked loss of CD4+ and CD8+ immune effector cells, a hallmark of septic shock and a likely key mechanism in its morbidity and mortality.